Incyte (INCY) announced that the company’s board of directors has unanimously appointed Bill Meury as president and CEO and a member of the company’s board of directors, effective immediately. Meury succeeds Herve Hoppenot who will retire from the company after 11 years of service. Hoppenot will serve as an advisor to the CEO and will remain as a member of the board through the end of the year to ensure a transition. In addition, lead independent director Julian Baker has been elected chairman of the board of directors. Meury most recently served as CEO of Anthos Therapeutics.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Monjuvi’s Strategic Advantage in Follicular Lymphoma: Analyst Recommends Buy Amid FDA Approval and Projected Revenue Growth
- J&J’s ‘968 delay has mixed readthroughs for Incyte’s ‘989, says RBC
- Sutro, Sarepta, Incyte, Signet, Wix: Trending by Analysts
- Incyte announces FDA extends review period for Opzelura sNDA
- Incyte confirms FDA approval of Monjuvi for refractory follicular lymphoma